

A Phase 1 Study of HB2198 in Participants With Moderately to Severely Active Systemic Lupus Erythematosus (SLE)

NCT07491900

Status	RECRUITING
Phase	Phase 1
Sponsor	Hinge Bio
Enrollment	30 participants

Key Eligibility Criteria

Inclusion (16)

- Meet 2019 ACR / 2023 EULAR SLE classification criteria
- Moderate or high disease activity (SLEDAI 2K e6; PGA e1)
- LN participants: biopsy confirmed active Class III/IV ± V or Class V LN; proteinuria e0.8 g/g; eGFR e30 mL/min/1.73 m²
- ERL participants: inadequate response/intolerance to e1 standard SLE therapy
- Positive ANA (e1:80) or SLE associated autoantibodies

... and 11 more (see full listing online)

Exclusion (11)

- Anti CD19 or anti CD20 therapy within 6 months
- Active CNS lupus
- Significant cardiovascular, pulmonary, hepatic, or uncontrolled systemic disease
- Active infection or recent serious infection
- Positive HBV DNA or HCV RNA; HIV infection

... and 6 more (see full listing online)

Locations (1 total)

Investigational site, Brisbane, Australia